Adoptive immunotherapy for gastric cancer using zoledronate‑activated killer cells: A prospective observational study Corrigendum in /10.3892/mco.2021.2454

Yamaguchi,Yoshiyuki; Katata,Yousuke; Sano,Fuminori; Tanioka,Hiroaki; Okawaki,Makoto; Yamamura,Masahiro; Nagasaka,Takeshi

doi:10.3892/mco.2020.2125

Adoptive immunotherapy for gastric cancer using zoledronate‑activated killer cells: A prospective observational study

Corrigendum in: /10.3892/mco.2021.2454

Authors:
- Yoshiyuki Yamaguchi
- Yousuke Katata
- Fuminori Sano
- Hiroaki Tanioka
- Makoto Okawaki
- Masahiro Yamamura
- Takeshi Nagasaka
View Affiliations

Affiliations: Department of Clinical Oncology, Kawasaki Medical School and Hospital, Kurashiki, Okayama 701‑0192, Japan
Published online on: August 24, 2020 https://doi.org/10.3892/mco.2020.2125
Article Number: 55
Copyright: © Yamaguchi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

For several years, adoptive immunotherapy (AIT) has been performed using autologous zoledronate‑activated killer (ZAK) cells to develop a novel modality for cancer treatment. In the current study, data from 50 patients with incurable gastric cancer were analyzed. Patients were treated with AIT using intravenous ZAK cells every 3‑4 weeks in combination with chemotherapy of the physician’s choice. The possible clinical benefits were subsequently examined. The median overall survival (OS) time of all patients was 7.5 months. In patients that received 5 or more rounds of treatment, the OS was 13.5 months. Additionally, the OS times of 1st, 2nd or later line chemotherapy with ZAK cell AIT were 27.3 months and 13.3 months, respectively. No objective response was observed and the disease control rate was 67.9%. No severe adverse event was recorded. Functional Assessment of Cancer Therapy‑Biologic Response Modifier analysis revealed possible improvement of quality of life after ZAK cell AIT. Univariate analysis revealed a significant positive association between longer survival times and baseline lymphocyte percentages in white blood cell counts (P<0.001), serum albumin (P=0.001), C‑reactive protein (P=0.006), carbohydrate antigen (CA)19‑9 (P=0.010), neutrophil‑lymphocyte ratio (P<0.001) and Glasgow prognostic score (GPS). Only the GPS value (P=0.024) was a significant survival marker when analyzed using the multivariate Cox proportional hazards model. Although the results cannot provide a definitive conclusion, the current suggested that ZAK cell AIT in combination with chemotherapy is safe, feasible and may be a promising treatment option for patients with incurable gastric cancer. The GPS value at baseline may be a potential biomarker for chemo‑immunotherapy.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
2	Yamaguchi Y, Ohshita A, Kawabuchi Y, Ohta K, Shimizu K, Minami K, Hihara J, Miyahara E and Toge T: Adoptive immunotherapy of cancer using activated autologous lymphocytes-current status and new strategies. Hum Cell. 16:183–189. 2003.PubMed/NCBI View Article : Google Scholar
3	Yamaguchi Y, Ohta K, Kawabuchi Y, Ohshita A, Okita R, Okawaki M, Hironaka K, Matsuura K and Toge T: Feasibility study of adoptive immunotherapy for metastatic lung tumors using peptide-pulsed dendritic cell-activated killer (PDAK) cells. Anticancer Res. 25:2407–2415. 2005.PubMed/NCBI
4	Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y and Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet. 356:802–807. 2000.PubMed/NCBI View Article : Google Scholar
5	Kimura H and Yamaguchi Y: A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer. 80:42–49. 1997.PubMed/NCBI
6	Nagamine I, Yamaguchi Y, Ohara M, Ikeda T and Okada M: Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer. Hiroshima J Med Sci. 58:37–44. 2009.PubMed/NCBI
7	Braza MS and Klein B: Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: From the bench to the bedside. Br J Haematol. 160:123–132. 2013.PubMed/NCBI View Article : Google Scholar
8	Brandes M, Willimann K and Moser B: Professional antigen-presentation function by human gammadelta T cells. Science. 309:264–268. 2005.PubMed/NCBI View Article : Google Scholar
9	Sakamoto M, Nakajima J, Murakawa T, Fukami T, Yoshida Y, Murayama T, Takamoto S, Matsushita H and Kakimi K: Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: A phase I clinical study. J Immunother. 34:202–211. 2011.PubMed/NCBI View Article : Google Scholar
10	Noguchi A, Kaneko T, Kamigaki T, Fujimoto K, Ozawa M, Saito M, Ariyoshi N and Goto S: Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors. Cytotherapy. 13:92–97. 2011.PubMed/NCBI View Article : Google Scholar
11	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.PubMed/NCBI View Article : Google Scholar
12	Bacik J, Mazumdar M, Murphy BA, Fairclough DL, Eremenco S, Mariani T, Motzer RJ and Cella D: The functional assessment of cancer therapy-BRM (FACT-BRM): A new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res. 13:137–154. 2004.PubMed/NCBI View Article : Google Scholar
13	Yamaguchi Y, Katata Y, Okawaki M, Sawaki A and Yamamura M: A prospective observational study of adoptive immunotherapy for cancer using zoledronate-activated killer (ZAK) cells-an analysis for patients with incurable pancreatic cancer. Anticancer Res. 36:2307–2313. 2016.PubMed/NCBI
14	Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol. 9:215–221. 2008.PubMed/NCBI View Article : Google Scholar
15	Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, et al: Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: A randomized study (START). J Cancer Res Clin Oncol. 140:319–328. 2014.PubMed/NCBI View Article : Google Scholar
16	Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235. 2014.PubMed/NCBI View Article : Google Scholar
17	Qiao G, Wang X, Zhou L, Zhou X, Song Y, Wang S, Zhao L, Morse MA, Hobeika A, Song J, et al: Autologous dendritic cell-cytokine induced killer cell immunotherapy combined with S-1 plus cisplatin in patients with advanced gastric cancer: A prospective study. Clin Cancer Res. 25:1494–1504. 2019.PubMed/NCBI View Article : Google Scholar
18	Kono K, Ichihara F, Iizuka H, Sekikawa T and Matsumoto Y: Expression of signal transducing T-cell receptor zeta molecules after adoptive immunotherapy in patients with gastric and colon cancer. Int J Cancer. 78:301–305. 1998.PubMed/NCBI View Article : Google Scholar
19	Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 390:2461–2471. 2017.PubMed/NCBI View Article : Google Scholar
20	Iwasaki M, Tanaka Y, Kobayashi H, Murata-Hirai K, Miyabe H, Sugie T, Toi M and Minato N: Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens. Eur J Immunol. 41:345–355. 2011.PubMed/NCBI View Article : Google Scholar
21	Zhao W, Jia L, Zhang M, Huang X, Qian P, Tang Q, Zhu J and Feng Z: The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer. Am J Cancer Res. 9:1846–1856. 2019.PubMed/NCBI
22	Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363:411–422. 2010.PubMed/NCBI View Article : Google Scholar
23	Hirahara T, Arigami T, Yanagita S, Matsushita D, Uchikado Y, Kita Y, Mori S, Sasaki K, Omoto I, Kurahara H, et al: Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer. 19(672)2019.PubMed/NCBI View Article : Google Scholar
24	Yuan SQ, Nie RC, Chen YM, Qiu HB, Li XP, Chen XJ, Xu LP, Yang LF, Sun XW, Li YF, et al: Glasgow prognostic score is superior to ECOG PS as a prognostic factor in patients with gastric cancer with peritoneal seeding. Oncol Lett. 15:4193–4200. 2018.PubMed/NCBI View Article : Google Scholar